Gilead Sciences Inc (GILD)
Payables turnover
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Cost of revenue | US$ in thousands | 6,251,000 | 5,804,000 | 5,657,000 | 6,601,000 | 4,572,000 |
Payables | US$ in thousands | — | — | — | — | — |
Payables turnover | — | — | — | — | — |
December 31, 2024 calculation
Payables turnover = Cost of revenue ÷ Payables
= $6,251,000K ÷ $—K
= —
Based on the provided data, Gilead Sciences Inc has not reported any specific figures for payables turnover for the years ending December 31, 2020, 2021, 2022, 2023, and 2024. This lack of information makes it challenging to assess the efficiency of Gilead's accounts payable management during these periods. It is advisable for stakeholders and investors to seek additional financial data or disclosures from the company to gain insights into its payables turnover performance.
Peer comparison
Dec 31, 2024
Company name
Symbol
Payables turnover
Gilead Sciences Inc
GILD
—
ADMA Biologics Inc
ADMA
10.23
Amgen Inc
AMGN
—
Bio-Techne Corp
TECH
25.82
Biogen Inc
BIIB
12.10
Halozyme Therapeutics Inc
HALO
—
Krystal Biotech Inc
KRYS
22.81
Moderna Inc
MRNA
—
Neurocrine Biosciences Inc
NBIX
—
Repligen Corporation
RGEN
—
Vericel Corp Ord
VCEL
—